NO953684L - Fremgangsmåte for fremstilling av kreftvaksiner - Google Patents
Fremgangsmåte for fremstilling av kreftvaksinerInfo
- Publication number
- NO953684L NO953684L NO953684A NO953684A NO953684L NO 953684 L NO953684 L NO 953684L NO 953684 A NO953684 A NO 953684A NO 953684 A NO953684 A NO 953684A NO 953684 L NO953684 L NO 953684L
- Authority
- NO
- Norway
- Prior art keywords
- dna
- cancer vaccines
- preparing cancer
- binding substance
- complex
- Prior art date
Links
- 229940022399 cancer vaccine Drugs 0.000 title abstract 2
- 238000009566 cancer vaccine Methods 0.000 title abstract 2
- 238000000034 method Methods 0.000 title 1
- 230000004568 DNA-binding Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- 108010039918 Polylysine Proteins 0.000 abstract 1
- 102000004338 Transferrin Human genes 0.000 abstract 1
- 108090000901 Transferrin Proteins 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000000021 endosomolytic effect Effects 0.000 abstract 1
- 210000002950 fibroblast Anatomy 0.000 abstract 1
- 230000003308 immunostimulating effect Effects 0.000 abstract 1
- 229920000656 polylysine Polymers 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 239000012581 transferrin Substances 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- 241000701161 unidentified adenovirus Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/55—IL-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/57—IFN-gamma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10361—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/20011—Rhabdoviridae
- C12N2760/20111—Lyssavirus, e.g. rabies virus
- C12N2760/20122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Biomedical Technology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Kreftvaksine oppnås ved behandling av tumorceller eller fibroblaster med et kompleks av DNA som koder for et immun- stimulerende polypeptid, og en DNA-bindende substans, f.eks. polylysin, som fortrinnsvis er konjugert med transferrin. Komplekset inneholder videre et konjugat av DNA-bindende substans og et til dette ionisk bundet endosomolytisk peptid eller et adenovirus, som oppviser i det minste en E4-defekt.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AT0055693A AT399656B (de) | 1993-03-19 | 1993-03-19 | Verfahren zur herstellung von krebsvakzinen |
DE4326821A DE4326821A1 (de) | 1993-08-10 | 1993-08-10 | Verfahren zur Herstellung von Krebsvakzinen |
PCT/EP1994/000859 WO1994021808A1 (de) | 1993-03-19 | 1994-03-18 | Verfahren zur herstellung von krebsvakzinen |
Publications (2)
Publication Number | Publication Date |
---|---|
NO953684L true NO953684L (no) | 1995-09-18 |
NO953684D0 NO953684D0 (no) | 1995-09-18 |
Family
ID=25593140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO953684A NO953684D0 (no) | 1993-03-19 | 1995-09-18 | Fremgangsmåte for fremstilling av kreftvaksiner |
Country Status (13)
Country | Link |
---|---|
EP (1) | EP0689604A1 (no) |
JP (1) | JPH08507921A (no) |
KR (1) | KR960701211A (no) |
CN (1) | CN1119459A (no) |
AU (1) | AU6427994A (no) |
CA (1) | CA2158655A1 (no) |
CZ (1) | CZ241795A3 (no) |
FI (1) | FI954383A0 (no) |
HU (1) | HUT73383A (no) |
NO (1) | NO953684D0 (no) |
NZ (1) | NZ263550A (no) |
PL (1) | PL311036A1 (no) |
WO (1) | WO1994021808A1 (no) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2190290C (en) * | 1994-05-13 | 2011-07-05 | Michael J. Mastrangelo | A method of inducing an immune response using vaccinia virus recombinants |
US6093700A (en) | 1995-05-11 | 2000-07-25 | Thomas Jefferson University | Method of inducing an immune response using vaccinia virus recombinants encoding GM-CSF |
DE4426429A1 (de) * | 1994-07-26 | 1996-02-01 | Boehringer Ingelheim Int | Verfahren zum Einführen von DNA in höhere eukaryotische Zellen |
DE19510344C1 (de) * | 1995-03-22 | 1996-11-07 | Boehringer Ingelheim Int | Verwendung einer Tumorvakzine |
AU6282896A (en) * | 1995-06-19 | 1997-01-15 | University Of Medicine And Dentistry Of New Jersey | Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins |
DE19608751B4 (de) * | 1996-03-06 | 2006-05-18 | Medigene Ag | Verwendung eines Adeno-assoziierten Virus-Vektors zur Steigerung der Immunogenität von Zellen |
DE19608753C1 (de) * | 1996-03-06 | 1997-06-26 | Medigene Gmbh | Transduktionssystem und seine Verwendung |
US7001765B2 (en) | 1996-03-06 | 2006-02-21 | Medigene Ag | Adeno-associated virus vector for boosting immunogenicity of cells |
DE19631357A1 (de) * | 1996-08-02 | 1998-02-05 | Deutsches Krebsforsch | Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen |
ATE208369T1 (de) | 1997-08-13 | 2001-11-15 | Biontex Lab Gmbh | Neue lipopolyamine, deren darstellung und anwendung |
CN100352511C (zh) * | 1997-08-13 | 2007-12-05 | Uab研究基金会 | 局部应用基因载体的疫苗接种 |
WO1999036433A2 (en) | 1998-01-14 | 1999-07-22 | Morphogenesis, Inc. | Materials and methods for treating oncological disease |
US7795020B2 (en) | 1998-01-14 | 2010-09-14 | Morphogenesis, Inc. | Tumor cell vaccines |
US7348015B2 (en) | 1998-01-14 | 2008-03-25 | Morphogenesis, Inc. | Antigen modified cancer cell vaccines for cancer therapy |
AU757600B2 (en) | 1998-02-20 | 2003-02-27 | University Of Miami | Modified heat shock protein-antigenic peptide complex |
EP1159967B1 (en) | 1999-02-09 | 2008-09-10 | Riken | Tumor vaccines |
BR0001029A (pt) * | 2000-04-10 | 2001-11-20 | Fk Biotecnologia Ltda | Processo de transformação de células tumorais |
AUPQ755300A0 (en) | 2000-05-17 | 2000-06-08 | Monash University | Immune potentiating compositions |
DE10131148A1 (de) * | 2001-06-28 | 2003-01-16 | I P L Internat Pharmaceutics L | Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren |
US7176022B2 (en) | 2002-12-20 | 2007-02-13 | Cell Genesys, Inc. | Directly injectable formulations which provide enhanced cryoprotection of cell products |
CA2717854C (en) | 2008-03-03 | 2019-02-19 | The University Of Miami | Allogeneic cancer cell-based immunotherapy |
EP2274001A4 (en) | 2008-03-20 | 2012-08-01 | Univ Miami | GP96 THERMAL IMPACT PROTEIN VACCINATION AND METHODS OF USE |
UA110119C2 (xx) * | 2010-12-02 | 2015-11-25 | Пептиди tomm34 та вакцини, що їх містять | |
SG11201705844SA (en) | 2015-02-06 | 2017-08-30 | Heat Biologics Inc | Vector co-expressing vaccine and costimulatory molecules |
CA3031806A1 (en) * | 2016-07-25 | 2018-02-01 | Ascend Biopharmaceuticals Ltd | Methods of treating cancer |
US11666649B2 (en) | 2016-10-11 | 2023-06-06 | University Of Miami | Vectors and vaccine cells for immunity against Zika virus |
WO2018187260A1 (en) | 2017-04-04 | 2018-10-11 | Heat Biologics, Inc. | Intratumoral vaccination |
SG11202005934WA (en) * | 2017-12-29 | 2020-07-29 | Genemedicine Co Ltd | Cell sheet for gene delivery |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ244306A (en) * | 1991-09-30 | 1995-07-26 | Boehringer Ingelheim Int | Composition for introducing nucleic acid complexes into eucaryotic cells, complex containing nucleic acid and endosomolytic agent, peptide with endosomolytic domain and nucleic acid binding domain and preparation |
-
1994
- 1994-03-18 AU AU64279/94A patent/AU6427994A/en not_active Abandoned
- 1994-03-18 HU HU9502720A patent/HUT73383A/hu unknown
- 1994-03-18 CN CN94191520A patent/CN1119459A/zh active Pending
- 1994-03-18 WO PCT/EP1994/000859 patent/WO1994021808A1/de not_active Application Discontinuation
- 1994-03-18 NZ NZ263550A patent/NZ263550A/en unknown
- 1994-03-18 CZ CZ952417A patent/CZ241795A3/cs unknown
- 1994-03-18 CA CA002158655A patent/CA2158655A1/en not_active Abandoned
- 1994-03-18 EP EP94911921A patent/EP0689604A1/de not_active Withdrawn
- 1994-03-18 PL PL94311036A patent/PL311036A1/xx unknown
- 1994-03-18 JP JP6520658A patent/JPH08507921A/ja active Pending
-
1995
- 1995-08-28 KR KR1019950703645A patent/KR960701211A/ko not_active Application Discontinuation
- 1995-09-18 NO NO953684A patent/NO953684D0/no unknown
- 1995-09-18 FI FI954383A patent/FI954383A0/fi unknown
Also Published As
Publication number | Publication date |
---|---|
FI954383A (fi) | 1995-09-18 |
WO1994021808A1 (de) | 1994-09-29 |
KR960701211A (ko) | 1996-02-24 |
HUT73383A (en) | 1996-07-29 |
AU6427994A (en) | 1994-10-11 |
CA2158655A1 (en) | 1994-09-29 |
NO953684D0 (no) | 1995-09-18 |
NZ263550A (en) | 1996-12-20 |
CZ241795A3 (en) | 1996-04-17 |
CN1119459A (zh) | 1996-03-27 |
PL311036A1 (en) | 1996-01-22 |
JPH08507921A (ja) | 1996-08-27 |
FI954383A0 (fi) | 1995-09-18 |
EP0689604A1 (de) | 1996-01-03 |
HU9502720D0 (en) | 1995-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO953684L (no) | Fremgangsmåte for fremstilling av kreftvaksiner | |
TW581808B (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
MY119276A (en) | Pharmaceutical composition for immunomodulation based on peptides and adjuvants | |
WO1998037093A3 (en) | Compounds for immunotherapy of prostate cancer and methods for their use | |
DK0835133T3 (da) | Rekombinant koppevirus-rabies-præparater og kombinationspræparater samt anvendelser deraf | |
ATE332386T1 (de) | Defektive rekombinante adenoviren zur tumor- gentherapie | |
PH25747A (en) | Recombinant vaccinia vrus mva | |
DK0584266T3 (da) | Rekombinant virus udtrykkende carcinoembryonalt antigen og fremgangsmåder til anvendelse heraf | |
DE69333815D1 (de) | Gentranskription und ionisierende strahlung: methoden und zusammensetzungen | |
BR9908823A (pt) | Compostos e processos para terapia e diagnóstico de câncer de pulmão | |
ATE282434T1 (de) | Eine zusammensetzung enthaltend eine detergenz und einen ein tumorsuppressorgen kodierenden, adenoviralen vektor | |
IL122408A0 (en) | Dna encoding a trail polypeptide and its preparation | |
CY1105597T1 (el) | Ανοσοθεραπευτικες μεθοδοι χρησιμοποιωντας επιτοπους των wt-1 και gata-1 | |
WO1995031559A3 (en) | Methods of inducing gene expression by ionizing radiation | |
DE68915165D1 (de) | Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3. | |
ATE424410T1 (de) | Interleukin-19. | |
DK0572688T3 (da) | Peptider, med organ-beskyttende aktivitet, fremgangsmåde til deres fremstilling og deres anvendelse ved terapi | |
DK1253201T3 (da) | Kyllingeanæmivirusmutanter og vacciner baseret på det virale protein VP3 eller sekvenser af dette virus kodende derfor | |
NO984052D0 (no) | Rekombinante, adenovirale vektorer for human tumorgenterapi | |
EP0236977A3 (en) | Bovine virus diarrhea and hog cholera vaccines | |
BR0016740A (pt) | Antìgenos de esporozoìto de cryptosporidium | |
EP2003201A3 (en) | Compounds and methods for therapy and diagnosis of lung cancer |